LIPF

Across TCGA pan-cancer cohorts, LIPF Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LIPF data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher LIPF Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LIPF expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

BRCA, LUSC, and UCEC are the cancer types where LIPF Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.350	0.924	<.001	36	view →
LUSC	DFS	Median	All	0.158	0.664	<.001	21	view →
UCEC	DFS	Median	All	0.958	0.626	.023	8	view →
BLCA	OS	Median	IV	0.051	0.600	<.001	6	view →
STAD	OS	Median	All	1.000	0.654	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LIPF–BRCA (OS)

Open the BRCA breakdown →